Who is sponsoring NCT05878834?

NCT05878834 is sponsored by Chulalongkorn University.

What drugs are being tested in NCT05878834?

Interventions in NCT05878834: Beta-glucan supplement group, Placebo group.

What condition does NCT05878834 study?

NCT05878834 studies Chronic Obstructive Pulmonary Disease Patients.

Is NCT05878834 still recruiting?

NCT05878834 is currently status unknown. Last updated 30 May 2023.

Last reviewed 2023-05-30 · How we verify

NCT05878834

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Beta-glucan Supplement in Chronic Obstructive Pulmonary Disease Patients

Status unknown NA Last updated 30 May 2023

What this trial tests

NA trial testing Beta-glucan supplement group in Chronic Obstructive Pulmonary Disease Patients in 72 participants. Status unknown.

Timeline

25 May 2023

Primary endpoint
30 November 2023

20 December 2023

Quick facts

Lead sponsor	Chulalongkorn University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	72
Start date	25 May 2023
Primary completion	30 November 2023
Estimated completion	20 December 2023

Drugs / interventions tested

Beta-glucan supplement group
Placebo group

Conditions studied

Chronic Obstructive Pulmonary Disease Patients — all drugs for Chronic Obstructive Pulmonary Disease Patients →

Sponsor

Chulalongkorn University

Who can join

18 and older, any sex, with Chronic Obstructive Pulmonary Disease Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives of this study are to evaluate Efficacy and safety of beta-glucan supplement in chronic obstructive pulmonary disease patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Chulalongkorn University trials

Trials by the same sponsor.

NCT07458659 — Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myel · EARLY_PHASE1 · not yet recruiting
NCT07346118 — Fluid Balance Guided by Modified Venous Excess Ultrasonography Versus Standard Care in Patients With Acute Kidney Injury · NA · not yet recruiting
NCT07388862 — Comparison of Treatment Outcome of Pulpotomy With Versus Without Dental Operating Microscope in Carious Mature Permanent · EARLY_PHASE1 · not yet recruiting
NCT07373977 — Comparison of Postoperative Pain After Pulpotomy Performed With Versus Without Dental Operating Microscope in Carious Ma · EARLY_PHASE1 · not yet recruiting
NCT07078929 — Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05878834 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chulalongkorn University
Last refreshed: 30 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05878834.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing